CN121086984A - T细胞制备组合物和方法 - Google Patents

T细胞制备组合物和方法

Info

Publication number
CN121086984A
CN121086984A CN202511339181.5A CN202511339181A CN121086984A CN 121086984 A CN121086984 A CN 121086984A CN 202511339181 A CN202511339181 A CN 202511339181A CN 121086984 A CN121086984 A CN 121086984A
Authority
CN
China
Prior art keywords
cells
cell
population
antigen
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202511339181.5A
Other languages
English (en)
Chinese (zh)
Inventor
马里特·M·范布伦
迪维亚·瑞迪·伦卡拉
杰西卡·科勒
弗拉维安·杜瓦莱·布朗
克里斯蒂娜·墨菲·库克辛
约斯特·赫伊伯特·凡丹伯格
雷纳特·德贝尔
努尔·巴克
托恩·舒马赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Netherlands Cancer Institute
Aetna Usa Inc
Original Assignee
Netherlands Cancer Institute
Aetna Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Netherlands Cancer Institute, Aetna Usa Inc filed Critical Netherlands Cancer Institute
Publication of CN121086984A publication Critical patent/CN121086984A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/13B-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/30Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32T-cell receptors [TCR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4201Neoantigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4271Melanoma antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081Purging biological preparations of unwanted cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081Purging biological preparations of unwanted cells
    • C12N5/0087Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • C12N5/0638Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55Lung
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57Skin; melanoma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59Reproductive system, e.g. uterus, ovaries, cervix or testes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Moulding By Coating Moulds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Casting Or Compression Moulding Of Plastics Or The Like (AREA)
CN202511339181.5A 2019-05-08 2020-05-07 T细胞制备组合物和方法 Pending CN121086984A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962845251P 2019-05-08 2019-05-08
US62/845,251 2019-05-08
PCT/US2020/031898 WO2020227546A1 (en) 2019-05-08 2020-05-07 T cell manufacturing compositions and methods
CN202080050310.8A CN114096261B (zh) 2019-05-08 2020-05-07 T细胞制备组合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080050310.8A Division CN114096261B (zh) 2019-05-08 2020-05-07 T细胞制备组合物和方法

Publications (1)

Publication Number Publication Date
CN121086984A true CN121086984A (zh) 2025-12-09

Family

ID=73051205

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202511339181.5A Pending CN121086984A (zh) 2019-05-08 2020-05-07 T细胞制备组合物和方法
CN202080050310.8A Active CN114096261B (zh) 2019-05-08 2020-05-07 T细胞制备组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080050310.8A Active CN114096261B (zh) 2019-05-08 2020-05-07 T细胞制备组合物和方法

Country Status (15)

Country Link
US (1) US20220280621A1 (https=)
EP (1) EP3965784A4 (https=)
JP (2) JP7582971B2 (https=)
KR (2) KR102756321B1 (https=)
CN (2) CN121086984A (https=)
AR (1) AR118859A1 (https=)
AU (1) AU2020268397A1 (https=)
BR (1) BR112021022363A2 (https=)
CA (1) CA3137037A1 (https=)
IL (1) IL287874A (https=)
MX (1) MX2021013608A (https=)
PH (1) PH12021552829A1 (https=)
SG (1) SG11202112346WA (https=)
TW (2) TWI777160B (https=)
WO (1) WO2020227546A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101122B1 (en) 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
PT2812431T (pt) 2012-02-09 2019-10-18 Baylor College Medicine Pepmixes para gerar ctls multivirais com larga especifidade
JP6999941B2 (ja) 2015-09-18 2022-02-10 ベイラー カレッジ オブ メディスン 病原体からの免疫原性抗原同定および臨床的有効性との相関
CA3081840A1 (en) 2017-11-08 2019-05-16 Neon Therapeutics, Inc. T cell manufacturing compositions and methods
KR20210040355A (ko) * 2018-06-19 2021-04-13 바이오엔테크 유에스 인크. 네오항원 및 이의 용도
TWI777160B (zh) * 2019-05-08 2022-09-11 美商百歐恩泰美國公司 T細胞製備組合物及方法
EP4114400A4 (en) * 2020-03-05 2023-10-18 Exuma Biotech Corp. Methods and compositions for the delivery of modified lymphocyte aggregates
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
US20230374455A1 (en) * 2020-08-13 2023-11-23 Biontech Us Inc. T cell manufacturing compositions and methods
US11948694B2 (en) * 2021-05-12 2024-04-02 Merative Us L.P. Controlling compartmental flows in epidemiological modeling based on mobility data
US12062456B2 (en) 2021-05-27 2024-08-13 Merative Us L.P. Hypothetical scenario evaluation in infectious disease dynamics based on similar regions
IL312121A (en) * 2021-10-15 2024-06-01 Biontech Us Inc T cell manufacturing compositions and methods
WO2023159088A1 (en) * 2022-02-15 2023-08-24 Marker Therapeutics, Inc. Compositions and methods for antigen-specific t cell expansion
IL321246A (en) * 2022-12-09 2025-08-01 Biontech Us Inc Compositions and methods for producing T cells
WO2024151124A1 (ko) * 2023-01-12 2024-07-18 주식회사 이뮤노맥스 항암능이 우수한 기억 t 세포 유래 면역세포치료제의 제조방법
CN117417886B (zh) * 2023-10-20 2024-05-14 广东壹加再生医学研究院有限公司 一种负载肿瘤抗原的树突状细胞激活的t淋巴细胞的培养方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276478B2 (en) * 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
WO2006110582A1 (en) * 2005-04-08 2006-10-19 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
DE102005046490A1 (de) * 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US9809797B2 (en) * 2007-10-03 2017-11-07 National Institutes Of Health (Nih) U.S. Dept. Of Health And Human Services (Dhhs) Division Of Extramural Inventions And Technology Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression
EP2749639B1 (en) * 2012-02-10 2016-10-12 Hakushinkouseikai Foundation Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine
RU2763795C2 (ru) * 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
DE102015214780A1 (de) * 2015-08-03 2017-02-09 Continental Automotive Gmbh Verfahren zur Erkennung fehlerhafter Komponenten eines Kraftstoffeinspritzsystems
AU2016306408B2 (en) * 2015-08-10 2021-02-11 Toray Industries, Inc. Immune inducer
EP3347051A4 (en) * 2015-09-10 2019-04-24 Affigen, Inc. SEQUENCING SELECTING TUMOR THEROSTICAS
WO2017059557A1 (en) * 2015-10-09 2017-04-13 Peking University Methods for enhancing in vivo persistence and efficacy of exogenously administered t cells, genetically modified t cells and method and method of use
AU2018337960B2 (en) * 2017-09-20 2025-08-14 Neximmune, Inc. Cell compositions comprising antigen-specific T cells for adoptive therapy
CA3081840A1 (en) * 2017-11-08 2019-05-16 Neon Therapeutics, Inc. T cell manufacturing compositions and methods
TWI777160B (zh) * 2019-05-08 2022-09-11 美商百歐恩泰美國公司 T細胞製備組合物及方法

Also Published As

Publication number Publication date
MX2021013608A (es) 2022-01-31
KR20240161214A (ko) 2024-11-12
AU2020268397A1 (en) 2022-01-06
AR118859A1 (es) 2021-11-03
EP3965784A4 (en) 2023-06-21
PH12021552829A1 (en) 2023-01-16
SG11202112346WA (en) 2021-12-30
CN114096261B (zh) 2025-09-26
BR112021022363A2 (pt) 2022-03-22
EP3965784A1 (en) 2022-03-16
KR20220044242A (ko) 2022-04-07
KR102756321B1 (ko) 2025-01-16
CN114096261A (zh) 2022-02-25
WO2020227546A1 (en) 2020-11-12
TW202248419A (zh) 2022-12-16
US20220280621A1 (en) 2022-09-08
JP2024038503A (ja) 2024-03-19
JP2022531474A (ja) 2022-07-06
IL287874A (en) 2022-01-01
TWI777160B (zh) 2022-09-11
JP7582971B2 (ja) 2024-11-13
CA3137037A1 (en) 2020-11-12
TW202108761A (zh) 2021-03-01
TWI867324B (zh) 2024-12-21

Similar Documents

Publication Publication Date Title
CN114096261B (zh) T细胞制备组合物和方法
JP7728373B2 (ja) T細胞を製造する組成物及び方法
US20250195659A1 (en) T cell manufacturing compositions and methods
CN120641112A (zh) T细胞制备组合物和方法
US20260115288A1 (en) T cell manufacturing compositions and methods
CN118574629A (zh) T细胞制备组合物和方法
HK40071072A (en) T cell manufacturing compositions and methods
HK40115457A (zh) T细胞制备组合物和方法
HK40071072B (zh) T细胞制备组合物和方法
HK40039283A (en) T cell manufacturing compositions and methods

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination